Quest Diagnostics (FRA:QDI) Current Accrued Expense: €1,387 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:QDI Quest Diagnostics Inc FRA:QDI
74 GF Score
Price €208.30
GF Value €172.09
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Quest Diagnostics Current Accrued Expense?

Quest Diagnostics FRA:QDI 74 Current Accrued Expense is €1,387 Mil as of Jun. 2026. GuruFocus rates FRA:QDI with a GF Score™ of 74/100 and a GF Value™ of €172.09 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Quest Diagnostics's Current Accrued Expense for the quarter that ended in Jun. 2026 was €1,387 Mil.

Quest Diagnostics's quarterly Current Accrued Expense increased from Dec. 2025 (€796 Mil) to Mar. 2026 (€1,298 Mil) and increased from Mar. 2026 (€1,298 Mil) to Jun. 2026 (€1,387 Mil).

Quest Diagnostics's annual Current Accrued Expense increased from Dec. 2023 (€704 Mil) to Dec. 2024 (€817 Mil) but then declined from Dec. 2024 (€817 Mil) to Dec. 2025 (€796 Mil).

Quest Diagnostics Current Accrued Expense Related Terms

Quest Diagnostics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Quest Diagnostics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Quest Diagnostics Current Accrued Expense Chart

Quest Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 918.63 831.66 704.26 817.48 795.93

Quest Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,169.58 1,241.36 795.93 1,297.50 1,387.06
FRA:QDI
74GF Score
Quest Diagnostics Inc FRA:QDI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Quest Diagnostics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €1,387 Mil mean?
Quest Diagnostics (FRA:QDI) has a Current Accrued Expense of €1,387 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Quest Diagnostics and its competitors.
Is Quest Diagnostics' Current Accrued Expense too high?
Quest Diagnostics' current Current Accrued Expense is €1,387 Mil. Overall, Quest Diagnostics has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Quest Diagnostics' Current Accrued Expense compare to LH and MTD?
Quest Diagnostics' Current Accrued Expense of €1,387 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Quest Diagnostics and its competitors. Quest Diagnostics's current Current Accrued Expense is €1,387 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Quest Diagnostics (FRA:QDI) is currently considered Modestly Overvalued. The stock's GF Value™ is €172.09, compared to a current price of €208.30 — trading 21% above its estimated fair value. The current Current Accrued Expense is €1,387 Mil. Quest Diagnostics' overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Quest Diagnostics (FRA:QDI), the current Current Accrued Expense is €1,387 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Quest Diagnostics (FRA:QDI) Overvalued in 2026?

Based on GuruFocus' analysis, Quest Diagnostics stock appears to be overvalued. The current stock price of €208.30 is trading 21% above its estimated GF Value™ of €172.09. GuruFocus considers Quest Diagnostics to be Modestly Overvalued.

Key valuation signals for FRA:QDI:

  • Current Accrued Expense: €1,387 Mil
  • GF Value™: €172.09 vs. price of €208.30 (21% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the FRA:QDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Quest Diagnostics Business Description

Address 500 Plaza Drive, Secaucus, NJ, USA, 07094
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
74GF Score

Get the complete analysis for FRA:QDI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€208.30
Price
€172.09
GF Value